FI60501C - Foerfarande foer selektiv separering av interferon fraon interferon-raopreparat - Google Patents
Foerfarande foer selektiv separering av interferon fraon interferon-raopreparat Download PDFInfo
- Publication number
- FI60501C FI60501C FI771624A FI771624A FI60501C FI 60501 C FI60501 C FI 60501C FI 771624 A FI771624 A FI 771624A FI 771624 A FI771624 A FI 771624A FI 60501 C FI60501 C FI 60501C
- Authority
- FI
- Finland
- Prior art keywords
- interferon
- preparations
- column
- preparation
- buffer
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims description 64
- 108010050904 Interferons Proteins 0.000 title claims description 64
- 229940079322 interferon Drugs 0.000 title claims description 64
- 238000002360 preparation method Methods 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 8
- 238000001042 affinity chromatography Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000003367 polycyclic group Chemical group 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 31
- 229920002307 Dextran Polymers 0.000 description 27
- 229920002684 Sepharose Polymers 0.000 description 21
- 239000000872 buffer Substances 0.000 description 20
- 239000000499 gel Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical group Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 239000003463 adsorbent Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001064 anti-interferon Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- -1 polycyclic compound Chemical class 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (8)
1. Förfarande för selektiv separering av interferon genom användning av affinitets-kromatografi frän ett interferon-rapreparat innehallande som förorening andra proteiner, vid vilket förfarande interferon-rapreparatet försätts i kontakt med en adsorbator, som bestir av en bärarsubstans samt en därtill ansluten, som ligand för interferon verkande förening och interferonet desorberas, k ä n n e -tecknat av att som ligand används en förening, som har den polycykliska strukturen av en bla kromofor enligt formeln
0 Niili I SO-ONa i^yVS^ /r ^VV /«—o S L —Q- h„ -ηΠη SO-ONn ''OH
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7615414A FR2351665A1 (fr) | 1976-05-21 | 1976-05-21 | Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament |
| FR7615414 | 1976-05-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI771624A7 FI771624A7 (sv) | 1977-11-22 |
| FI60501B FI60501B (fi) | 1981-10-30 |
| FI60501C true FI60501C (fi) | 1983-06-06 |
Family
ID=9173478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI771624A FI60501C (fi) | 1976-05-21 | 1977-05-20 | Foerfarande foer selektiv separering av interferon fraon interferon-raopreparat |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4172071A (sv) |
| BE (1) | BE854916A (sv) |
| DE (1) | DE2722970A1 (sv) |
| FI (1) | FI60501C (sv) |
| FR (1) | FR2351665A1 (sv) |
| GB (1) | GB1585601A (sv) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410697B1 (en) * | 1979-04-20 | 2002-06-25 | Schering Corporation | Process for purifying human leukocyte interferon |
| FI77877C (sv) * | 1979-04-20 | 1989-05-10 | Technobiotic Ltd | Förfarande för framställning och rening av human Le-formig interferonp rotein. |
| JPS5651995A (en) * | 1979-10-05 | 1981-05-09 | Green Cross Corp:The | Preparation of interferon |
| US4278661A (en) * | 1979-10-12 | 1981-07-14 | E. I. Du Pont De Nemours And Company | Purification of interferon |
| US4824432A (en) * | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
| US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
| US4605394A (en) * | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
| JPS5821691A (ja) * | 1981-07-29 | 1983-02-08 | Mochida Pharmaceut Co Ltd | α−及びβ−インタ−フェロンの精製方法 |
| US4499014A (en) * | 1984-02-07 | 1985-02-12 | Interferon Sciences, Inc. | Method for purifying gamma-interferon |
| US4658017A (en) * | 1984-02-14 | 1987-04-14 | Health Research, Inc. (Roswell Park Division) | Method for the large scale purification of human fibroblast interferon |
| US4803163A (en) * | 1984-06-04 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Preparation of a protein fraction exhibiting cell growth-inhibiting activity |
| EP0195084B1 (de) * | 1984-09-21 | 1990-05-23 | Vsesojuzny Nauchno-Issledovatelsky Institut Osobo Chistykh Biopreparatov | Rektifizierungsverfahren menschlichen leukozyten-interferons |
| EP0190606B1 (de) * | 1985-02-04 | 1990-05-09 | F. Hoffmann-La Roche Ag | Adsorbens für die Reinigung von Proteinen |
| US5144013A (en) * | 1986-09-24 | 1992-09-01 | Ube Industries, Ltd. | Body fluid purifying material and method for purifying body fluid by use thereof |
| US5434249A (en) * | 1992-05-27 | 1995-07-18 | Viragen Inc. | Method for modulating specific activity of inteferon alpha |
| US20040199099A1 (en) * | 1998-07-10 | 2004-10-07 | Matson James R | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
| US6287516B1 (en) | 1998-07-10 | 2001-09-11 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
| US6736972B1 (en) | 2000-03-24 | 2004-05-18 | Immunocept, L.L.C. | Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases |
| US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
| US6787040B2 (en) * | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
| CA2469846A1 (en) | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
| CN1674955A (zh) * | 2002-08-13 | 2005-09-28 | 阿尔比奥技术公司 | 选择性血浆交换治疗 |
| US10953148B2 (en) * | 2013-12-27 | 2021-03-23 | Eliaz Therapeutics, Inc. | Plasmapheresis device |
| CN114041622B (zh) * | 2021-10-16 | 2023-06-27 | 深圳市真味生物科技有限公司 | 电子雾化液制备用甜味剂母液脱色的工艺 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB980227A (en) * | 1962-08-16 | 1965-01-13 | Glaxo Lab Ltd | Purification and/or concentration of material containing interferon |
| GB1055896A (en) * | 1963-12-10 | 1967-01-18 | Glaxo Lab Ltd | Silica adsorbents in interferon purification and/or concentration |
| US3773924A (en) * | 1970-12-24 | 1973-11-20 | M Ho | Interferon production |
| FR2244543B1 (sv) * | 1973-07-27 | 1977-07-01 | Inst Nl Sante Rech Medica | |
| JPS5126900A (en) * | 1973-09-10 | 1976-03-05 | Research Corp | Ketsueki ryutai kara arubumin o sentakuteki ni jokyo suru hoho |
| US4016149A (en) * | 1973-09-10 | 1977-04-05 | Research Corporation | Selective removal of albumin from blood fluid and compositions therefore |
| NL7404589A (nl) * | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het stabiliseren van interferon. |
| US3975344A (en) * | 1974-10-02 | 1976-08-17 | G. D. Searle & Co. | Interferon purification |
-
1976
- 1976-05-21 FR FR7615414A patent/FR2351665A1/fr active Granted
-
1977
- 1977-05-19 US US05/798,523 patent/US4172071A/en not_active Expired - Lifetime
- 1977-05-20 FI FI771624A patent/FI60501C/fi not_active IP Right Cessation
- 1977-05-20 DE DE19772722970 patent/DE2722970A1/de not_active Withdrawn
- 1977-05-23 BE BE177808A patent/BE854916A/xx not_active IP Right Cessation
- 1977-05-23 GB GB21596/77A patent/GB1585601A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2351665B1 (sv) | 1978-12-08 |
| FR2351665A1 (fr) | 1977-12-16 |
| FI771624A7 (sv) | 1977-11-22 |
| GB1585601A (en) | 1981-03-11 |
| BE854916A (fr) | 1977-09-16 |
| DE2722970A1 (de) | 1977-12-08 |
| US4172071A (en) | 1979-10-23 |
| FI60501B (fi) | 1981-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI60501C (fi) | Foerfarande foer selektiv separering av interferon fraon interferon-raopreparat | |
| FI72124B (fi) | Foerfarande foer tillvaratagande av interferon | |
| ES2070919T5 (es) | Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno. | |
| AU621148B2 (en) | Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography | |
| CA1073815A (en) | Method for purification and isolation of hepatitis virus for use in the preparation of vaccine | |
| US4257938A (en) | Purification method of human fibroblast interferon | |
| JPS5944320A (ja) | C1不活性化剤の調製方法 | |
| US4440675A (en) | Human immune interferon | |
| US4382027A (en) | Purification of human immune interferon | |
| JPS6262153B2 (sv) | ||
| JPH0586097A (ja) | 上清iv、特にiv−4またはコーンフラクシヨンvまたはそれと類似の上清または画分からヒトアルブミンを単離する方法 | |
| JPS58201794A (ja) | ヒトインターフェロンβの濃縮精製法 | |
| JPS58159417A (ja) | 均一なヒトのインタ−フエロン及びその製造方法 | |
| JP2004511492A (ja) | ビクニンを含む血漿画分、その調製方法、およびその使用 | |
| US4617378A (en) | Purification of biologically active human immune interferon | |
| JPH07330626A (ja) | 血清アルブミン製剤の製造方法 | |
| CA1128418A (en) | Purification of gammaglobulin derivative | |
| ES2213155T3 (es) | Procedimiento para la preparacion de un concentrado de inhibidor de la c1-esterasa (c1-inh) y concentrado obtenido, para uso terapeutico. | |
| JP2521551B2 (ja) | 抗血友病因子の製造方法 | |
| FI62103C (fi) | Foerfarande foer framstaellning av heparin med hoeg specifik aktivitet | |
| GB1601744A (en) | Processes for the purification of interferon certain new and useful intermediates formed therein the purified interferon thus produced and pharmaceutical compositions containing | |
| CA2151597A1 (en) | Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein | |
| FUNATSU et al. | Structure and Toxic Function of Ricin I Purification Procedures of Ricin D | |
| JP2722140B2 (ja) | ヒト尿性トリプシンインヒビターの製造方法 | |
| JPH05170799A (ja) | ヒトインターロイキン8の精製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: AGENCE NATIONALE DE VALORISATION DE LA |